{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:00:17Z","timestamp":1781665217734,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T00:00:00Z","timestamp":1100822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1007\/s00204-004-0622-8","type":"journal-article","created":{"date-parts":[[2004,11,18]],"date-time":"2004-11-18T13:42:47Z","timestamp":1100785367000},"page":"196-200","source":"Crossref","is-referenced-by-count":38,"title":["Re-investigation of the concordance of human NAT2 phenotypes and genotypes"],"prefix":"10.1007","volume":"79","author":[{"given":"Hermann M.","family":"Bolt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Selinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Dannappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Blaszkewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Golka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,11,19]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/carcin\/14.8.1689","volume":"14","author":"Bell","year":"1993","unstructured":"Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH et al. (1993) Genotype\/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele in African?Americans. Carcinogenesis 14:1689?1692","journal-title":"Carcinogenesis"},{"key":"CR2","first-page":"59","volume":"31","author":"Braz","year":"1992","unstructured":"Braz Vieira de Silva Pontes Z, Vincent-Viry M, Gueguen R, Gatteau MM, Siest G (1992) Acetylation phenotypes and biological variation in a French Caucasian population. Eur J Clin Biochem 31:59?67","journal-title":"Eur J Clin Biochem"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.tpj.6500053","volume":"2","author":"Butcher","year":"2002","unstructured":"Butcher NJ, Boukouvala S, Sim E, Minchin RF (2002) Pharmacogenetics of arylamine N-acetyltransferases. Pharmacogenomics J 2:30?42","journal-title":"Pharmacogenomics J"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00008571-199206000-00003","volume":"2","author":"Butler","year":"1992","unstructured":"Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB et al. (1992) Determination of CYP1A1 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116?127","journal-title":"Pharmacogenetics"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00008571-199606000-00009","volume":"6","author":"Cascorbi","year":"1996","unstructured":"Cascorbi I, Brockm\u00f6ller J, Bauer S, Reum T, Roots I (1996) NAT2*12A (803A?G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 6:257?259","journal-title":"Pharmacogenetics"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajmg.1320570413","volume":"57","author":"Cascorbi","year":"1995","unstructured":"Cascorbi I, Drakoulis N, Brockm\u00f6ller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581?592","journal-title":"Am J Hum Genet"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00008571-199902000-00016","volume":"9","author":"Cascorbi","year":"1999","unstructured":"Cascorbi I, Roots T (1999) Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 9:123?127","journal-title":"Pharmacogenetics"},{"key":"CR8","unstructured":"DFG, Deutsche Forschungsgemeinschaft (2004a) N-Acetyltransferase 2 (genotyping). In: Angerer J, M\u00fcller M, Weiss T et al. (eds) Analyses of hazardous substances in biological materials, vol 9: Special issue: Markers of susceptibility. Wiley?VCH, Weinheim, pp 135?163"},{"key":"CR9","unstructured":"DFG, Deutsche Forschungsgemeinschaft (2004b) N-Acetyltransferase 2 (phenotyping). In: Angerer J, M\u00fcller M, Weiss T et al. (eds) Analyses of hazardous substances in biological materials, vol 9: Special issue: Markers of susceptibility. Wiley?VCH, Weinheim, pp 165?182"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0378-4274(01)00544-6","volume":"128","author":"Golka","year":"2002","unstructured":"Golka K, Prior V, Blaszkewicz M, Bolt HM (2002) The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 128:229?241","journal-title":"Toxicol Lett"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5271\/sjweh.150","volume":"22","author":"Golka","year":"1996","unstructured":"Golka K, Prior V, Blaszkewicz M, Cascorbi I, Sch\u00f6ps W, Kierfeld G et al. (1996) Occupational history and gene N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22:332?338","journal-title":"Scand J Work Environ Health"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0027-5107(97)00026-2","volume":"376","author":"Grant","year":"1997","unstructured":"Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376:61?70","journal-title":"Mutat Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2125.1984.tb02372.x","volume":"17","author":"Grant","year":"1984","unstructured":"Grant DM, Tang BK, Kalow W (1984) A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17:459?464","journal-title":"Br J Clin Pharmacol"},{"key":"CR14","first-page":"683","volume":"8","author":"Gross","year":"1999","unstructured":"Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 8:683?692","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/hmg\/3.5.729","volume":"3","author":"Hein","year":"1994","unstructured":"Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K (1994) Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant and chimeric NAT2 allozymes. Hum Mol Genet 3:729?734","journal-title":"Hum Mol Genet"},{"key":"CR16","first-page":"3531","volume":"55","author":"Hein","year":"1995","unstructured":"Hein DW, Doll MA, Rustan TD, Ferguson RJ (1995) Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 55:3531?3536","journal-title":"Cancer Res"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00008571-200006000-00002","volume":"10","author":"Hein","year":"2000","unstructured":"Hein DW, Grant DM, Sim E (2000a) Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10:291?292","journal-title":"Pharmacogenetics"},{"key":"CR18","first-page":"29","volume":"9","author":"Hein","year":"2000","unstructured":"Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH et al. (2000b) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29?42","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-199210000-00004","volume":"2","author":"Hickman","year":"1992","unstructured":"Hickman D, Risch A, Camilleri JP, Sim E (1992) Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 2:217?226","journal-title":"Pharmacogenetics"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"34519","DOI":"10.1074\/jbc.274.49.34519","volume":"274","author":"Leff","year":"1999","unstructured":"Leff MA, Fretland AJ, Doll MA, Hein DW (1999) Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem 274:34519?34522","journal-title":"J Biol Chem"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14622416.3.3.349","volume":"3","author":"Meisel","year":"2002","unstructured":"Meisel P (2002) Arylamine N-acetyltransferase and drug response. Pharmacogenomics 3:349?366","journal-title":"Pharmacogenomics"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-200003000-00009","volume":"10","author":"O","year":"2000","unstructured":"O?Neil WM, Drobitch RK, McArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW et al. (2000) Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 10:171?182","journal-title":"Pharmacogenetics"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14622416.3.1.19","volume":"3","author":"Pompeo","year":"2002","unstructured":"Pompeo F, Brooke E, Kawamura A, Mushtaq A, Sim E (2002) The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 3:19?30","journal-title":"Pharmacogenomics"},{"key":"CR24","first-page":"1526","volume":"52b","author":"R","year":"1997","unstructured":"R\u00f6hrkasten R, Raatz P, Kreher RP, Blaszkewicz M (1997) Synthesis of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 5-acetylamino-6-amino-3-methyluracil (AAMU) on a preparative scale. Z Naturforsch 52b:1526?1532","journal-title":"Z Naturforsch"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-199502000-00001","volume":"5","author":"Vatsis","year":"1995","unstructured":"Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM et al. (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1?17","journal-title":"Pharmacogenetics"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-004-0622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-004-0622-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-004-0622-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:21:48Z","timestamp":1558639308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-004-0622-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,19]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s00204-004-0622-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,19]]}}}